Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx.
Explore the source record for details and available documents.
Carcinoma, Squamous Cell↗
Biomedical subjects
H T Barkley
Publications and source records attributed to H T Barkley.
Evolution of the clinically negative neck in patients with squamous cell carcinoma of the faucial arch.
Explore the source record for details and available documents.
Carcinoma, Squamous Cell↗
Cancer of the oral cavity. Is elective neck dissection beneficial?
Explore the source record for details and available documents.
Carcinoma, Squamous Cell↗
Present status of the time factor in clinical radiotherapy. I. The historical background of the recovery exponents.
Explore the source record for details and available documents.
Breast Neoplasms↗
Combination chemotherapy with bleomycin (NSC-125066), vincristine (NSC-67574), and methotrexate (NSC-740) plus split-course radiotherapy in the treatment of non-oat-cell bronchogenic carcinoma.
Twenty-seven unselected patients with limited disease non-oat-cell bronchogenic carcinoma were treated with a chemotherapy- radiotherapy protocol which consisted of bleomycin, vincristine, and methotrexate followed by split-course radiation. There were 15 objective responders with a median survival time in excess of 70+ weeks in contrast to a median survival time of 26 weeks for nonresponders (P less than 0.01). Objective benefit was limited to the epidermoid carcinoma group since none of the adenocarcinoma group achieved a greater than 50% reduction in maximum tumor diameter. The median survival time for the entire groups was 42 weeks in contrast to a recent split-course radiotherapy historical control group whose median survival time was 38 weeks. Toxic effects were predominantly gastrointestinal.
Administration, Oral↗